Health Care·Pharmaceuticals·$277.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.36 | N/A | +5.84% |
management commentary, guidance changes, and full analysis available with Pro.
| +5.84% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative therapies.
This earnings report shows that Novartis managed to exceed EPS expectations, which may indicate strong operational performance. However, the lack of revenue data and guidance leaves some uncertainty for investors. The stock reaction is not available, making it difficult to assess market sentiment following the earnings release.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KONINKLIJKE PHILIPS ADR
Jul 20, 2020